title: French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends.
abstract: France is one of the European countries that spend the most on oncology drugs. To keep pharmaceutical expenditure under control, Health Authorities highly scrutinize market access of costly medicines.
  
  
  
  To assess current and future trends in French health technology assessment (HTA) of antineoplastic drugs indicated in the treatment of solid tumours.
  
  
  
  A review of the SMR and ASMR drivers of the Transparency Committee (CT) opinions issued for antineoplastic drugs indicated in the treatment of solid tumours and approved between 2009 and 2014 was performed to assess current trends in French health technology assessment (HTA), complemented by an expert board consultation to capture the critical issues on the future of antineoplastic drugs HTA.
  
  
  
  Thirty-one drugs indicated for the treatment of solid tumours were identified (77 % targeted therapies). Initial CT assessments were available for 26 drugs. Four key items in the CT assessment were identified: 1) Clinical trial methodology; 2) Acceptance of progression-free survival (PFS) as a valuable endpoint; 3) Transferability of clinical trials in clinical practice; 4) Unpredictability of CT decisions. Experts raised the important development of personalised medicines in oncology and key challenges for oncology products to generate information expected from HTA perspective.
  
  
  
  The French system remains committed to its values and philosophy (access of all innovations for everybody) which are threatened by the increasing launch of innovative therapies and budget constraint. Both HTA decision framework evolution and revision of the current pricing process should be considered in France to cope with these new challenges.
authors.affiliation: INSERM UMR U955, Faculté de Médecine, Université Paris Est (UPEC), F-94010, Créteil, France.|Département de Pneumologie et Pathologie Professionnelle, Centre Hospitalier Intercommunal, DHU-ATVB, F-94010, Créteil, France.
authors.forename: Christos
authors.initials: C
authors.lastname: Chouaid
authors.affiliation: Unité de Biostatistique et d'Epidemiologie, Institut Gustave Roussy, 94805, Villejuif, France.|Méthodologie et Epidémiologie Clinique en Oncologie Moléculaire, Equipe 2, INSERM U1018, Centre de recherche en épidémiologie et santé des populations, Institut Gustave Roussy, 94805, Villejuif, France.|Groupe de Recherche et d'Accueil en Droit et Économie de la Santé (GRADES), Faculté de Pharmacie, Université Paris-Sud, 92296, Châtenay-Malabry CEDEX, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Borget
authors.affiliation: Départment Market Access, Janssen, 92130, Issy-Les-Moulineaux, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Braun
authors.affiliation: Départment Market Access, Janssen, 92130, Issy-Les-Moulineaux, France.
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Bazil
authors.affiliation: Départment Market Access, Janssen, 92130, Issy-Les-Moulineaux, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Schaetz
authors.affiliation: Creativ-Ceutical, 75008, Paris, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Rémuzat
authors.affiliation: Laboratoire de Santé Publique, Faculté de Médecine, Aix-Marseille Université, 13015, Marseille Cedex, France. mondher.toumi@emaud.org.
authors.forename: Mondher
authors.initials: M
authors.lastname: Toumi
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D005602:France; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013673:Technology Assessment, Biomedical / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents
references.citation: Clin Cancer Res. 2013 May 15;19(10):2607-12
references.pmid: 23669420
references.citation: J Mark Access Health Policy. 2013 Aug 06;1:null
references.pmid: 27226825
references.citation: J Mark Access Health Policy. 2013 Aug 06;1:null
references.pmid: 27226829
references.citation: Clin Pharmacol Ther. 2015 Mar;97(3):234-46
references.pmid: 25669457
references.citation: Blood. 2013 May 30;121(22):4439-42
references.pmid: 23620577
references.citation: Lancet Oncol. 2013 Nov;14(12):1165-74
references.pmid: 24131614
references.citation: J Mark Access Health Policy. 2015 Mar 12;3:null
references.pmid: 27123190
references.citation: Therapie. 2015 Jan-Feb;70(1):1-19
references.pmid: 25679189